{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T17:46:45Z","timestamp":1793382405333,"version":"4.5.0"},"reference-count":35,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2013,6,1]],"date-time":"2013-06-01T00:00:00Z","timestamp":1370044800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,6,1]],"date-time":"2013-06-01T00:00:00Z","timestamp":1370044800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice & Research Clinical Endocrinology & Metabolism"],"published-print":{"date-parts":[[2013,6]]},"DOI":"10.1016\/j.beem.2013.02.008","type":"journal-article","created":{"date-parts":[[2013,3,27]],"date-time":"2013-03-27T09:46:56Z","timestamp":1364377616000},"page":"373-384","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":71,"title":["Calcimimetic and calcilytic drugs for treating bone and mineral-related disorders"],"prefix":"10.1016","volume":"27","author":[{"given":"Edward F.","family":"Nemeth","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dolores","family":"Shoback","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.beem.2013.02.008_bib1","doi-asserted-by":"crossref","DOI":"10.1016\/j.ddtec.2012.11.002","article-title":"Allosteric modulators of the extracellular calcium receptor","author":"Nemeth","year":"2013","journal-title":"Drug Discovery Today: Technologies"},{"key":"10.1016\/j.beem.2013.02.008_bib2","doi-asserted-by":"crossref","first-page":"5644","DOI":"10.1210\/jc.2002-021597","article-title":"The calcimimetic cinacalcet normalizes serum calcium in subjects with primary hyperparathyroidism","volume":"88","author":"Shoback","year":"2003","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"10.1016\/j.beem.2013.02.008_bib3","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1210\/jc.2004-0842","article-title":"Cinacalcet hydrochloride maintains long-term normocalcemia in patients with primary hyperparathyroidism","volume":"90","author":"Peacock","year":"2005","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"10.1016\/j.beem.2013.02.008_bib4","doi-asserted-by":"crossref","first-page":"4860","DOI":"10.1210\/jc.2009-1472","article-title":"Cinacalcet treatment of primary hyperparathyroidism: biochemical and bone densitometric outcomes in a five-year study","volume":"94","author":"Peacock","year":"2009","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"10.1016\/j.beem.2013.02.008_bib5","doi-asserted-by":"crossref","first-page":"2766","DOI":"10.1210\/jc.2008-2640","article-title":"Cinacalcet reduces serum calcium concentrations in patients with intractable primary hyperparathyroidism","volume":"94","author":"Marcocci","year":"2009","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"10.1016\/j.beem.2013.02.008_bib6","first-page":"351","article-title":"A patient with MEN1-associated hyperparathyroidism, responsive to cinacalcet","volume":"4","author":"Falchetti","year":"2008","journal-title":"Nature Clinical Practice: Endocrinology and Metabolism"},{"key":"10.1016\/j.beem.2013.02.008_bib7","doi-asserted-by":"crossref","first-page":"906163","DOI":"10.1155\/2010\/906163","article-title":"Clinical use of cinacalcet in MEN1 hyperparathyroidism","volume":"2010","author":"Moyes","year":"2010","journal-title":"International Journal of Endocrinology"},{"key":"10.1016\/j.beem.2013.02.008_bib8","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1530\/EJE-12-0117","article-title":"MEN1-related hyperparathyroidism: response to cinacalcet and its relationship with the calcium-sensing receptor gene variant Arg990Gly","volume":"167","author":"Filopanti","year":"2012","journal-title":"European Journal of Endocrinology"},{"key":"10.1016\/j.beem.2013.02.008_bib9","doi-asserted-by":"crossref","first-page":"E707","DOI":"10.1210\/jc.2010-1306","article-title":"Neonatal hyperparathyroidism with a heterozygous calcium-sensing receptor (CASR) R185Q mutation: clinical benefit from cinacalcet","volume":"96","author":"Reh","year":"2011","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"10.1016\/j.beem.2013.02.008_bib10","doi-asserted-by":"crossref","first-page":"e812","DOI":"10.1542\/peds.2011-0128","article-title":"Successful use of bisphosphonate and calcimimetic in neonatal severe primary hyperparathyroidism","volume":"129","author":"Wilhelm-Bals","year":"2012","journal-title":"Pediatrics"},{"key":"10.1016\/j.beem.2013.02.008_bib11","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1007\/s00467-010-1547-5","article-title":"Beneficial effect of cinacalcet in a child with familial hypocalciuric hypercalcemia","volume":"25","author":"Alon","year":"2010","journal-title":"Pediatric Nephrology"},{"key":"10.1016\/j.beem.2013.02.008_bib12","doi-asserted-by":"crossref","first-page":"3803","DOI":"10.1210\/jc.2007-0585","article-title":"Cinacalcet hydrochloride reduces the serum calcium concentration in inoperable parathyroid carcinoma","volume":"92","author":"Silverberg","year":"2007","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"10.1016\/j.beem.2013.02.008_bib13","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1359\/jbmr.070304","article-title":"Cinacalcet in the management of tumor-induced osteomalacia","volume":"22","author":"Geller","year":"2007","journal-title":"Journal of Bone and Mineral Research"},{"key":"10.1016\/j.beem.2013.02.008_bib14","doi-asserted-by":"crossref","first-page":"658","DOI":"10.2215\/CJN.04981107","article-title":"Calcimimetics as an adjuvant treatment for familial hypophosphatemic rickets","volume":"3","author":"Alon","year":"2008","journal-title":"Clinical Journal of the American Society of Nephrology"},{"key":"10.1016\/j.beem.2013.02.008_bib15","series-title":"The spectrum of mineral and bone disorders in chronic kidney disease","article-title":"Calcimimetics and calcilytics in the treatment of chronic kidney disease-mineral bone disorder","author":"Nemeth","year":"2010"},{"key":"10.1016\/j.beem.2013.02.008_bib16","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.1093\/ndt\/gfh966","article-title":"Long-term treatment of secondary hyperparathyroidism with the calcimimetic cinacalcet HCl","volume":"20","author":"Moe","year":"2005","journal-title":"Nephrology Dialysis Transplantation"},{"key":"10.1016\/j.beem.2013.02.008_bib17","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.2215\/CJN.01040308","article-title":"Cinacalcet HCl and concurrent low-dose vitamin D improves treatment of secondary hyperparathyroidism in dialysis patients compared with vitamin D alone: the ACHIEVE study results","volume":"3","author":"Fishbane","year":"2008","journal-title":"Clinical Journal of the American Society of Nephrology"},{"key":"10.1016\/j.beem.2013.02.008_bib18","doi-asserted-by":"crossref","first-page":"3270","DOI":"10.1093\/ndt\/gfs018","article-title":"Paracalcitol versus cinacalcet plus low-dose vitamin D therapy for the treatment of secondary hyperparathyroidism in patients receiving haemodialysis: results of the IMPACT SHPT study","volume":"27","author":"Ketteler","year":"2012","journal-title":"Nephrology Dialysis Transplantation"},{"key":"10.1016\/j.beem.2013.02.008_bib19","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1111\/j.1525-139X.2011.00935.x","article-title":"Does it matter how parathyroid hormone levels are suppressed in secondary hyperparathyroidism?","volume":"24","author":"Stubbs","year":"2011","journal-title":"Seminars in Dialysis"},{"key":"10.1016\/j.beem.2013.02.008_bib20","series-title":"Bone histomorphometry before and after 12 months of treatment with cinacalcet among dialysis patients with secondary hyperparathyroidism (HPT)","author":"Behets","year":"2012"},{"key":"10.1016\/j.beem.2013.02.008_bib21","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1111\/j.1542-4758.2011.00642.x","article-title":"Self-reported symptoms in patients on hemodialysis with moderate to severe secondary hyperparathryoidism receiving combined therapy with cinacalcet and low-dose vitamin D sterols","volume":"16","author":"Chertow","year":"2012","journal-title":"Hemodialysis International"},{"key":"10.1016\/j.beem.2013.02.008_bib22","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.2215\/CJN.02110310","article-title":"Cinacalcet effectively reduces parathyroid hormone secretion and gland volume regardless of pretreatment gland size in patients with secondary hyperparathyroidism","volume":"5","author":"Komaba","year":"2012","journal-title":"Clinical Journal of the American Society of Nephrology"},{"key":"10.1016\/j.beem.2013.02.008_bib23","doi-asserted-by":"crossref","first-page":"c195","DOI":"10.1159\/000313035","article-title":"Decreases in parathyroid gland volume after cinacalcet treatment in hemodialysis patients with secondary hyperparathyroidism","volume":"115","author":"Ichii","year":"2010","journal-title":"Nephron Clinical Practice"},{"key":"10.1016\/j.beem.2013.02.008_bib24","doi-asserted-by":"crossref","first-page":"c187","DOI":"10.1159\/000262301","article-title":"Response of secondary hyperparathyroidism to cinacalcet depends on parathyroid size","volume":"114","author":"Hirai","year":"2010","journal-title":"Nephron Clinical Practice"},{"key":"10.1016\/j.beem.2013.02.008_bib25","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1093\/ndt\/gfq725","article-title":"The ADVANCE study: a randomized study to evaluate the effects of cinacalcet plus low-dose vitamin D on vascular calcification in patients on hemodialysis","volume":"26","author":"Raggi","year":"2011","journal-title":"Nephrology Dialysis Transplantation"},{"key":"10.1016\/j.beem.2013.02.008_bib26","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1038\/ki.2010.167","article-title":"Cinacalcet hydrochloride treatment significantly improves all-cause and cardiovascular survival in a large cohort of hemodialysis patients","volume":"78","author":"Block","year":"2010","journal-title":"Kidney International"},{"key":"10.1016\/j.beem.2013.02.008_bib27","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1038\/ki.2010.220","article-title":"Lead-time bias in studies of cinacalcet presciptions","volume":"78","author":"Evans","year":"2010","journal-title":"Kidney International"},{"key":"10.1016\/j.beem.2013.02.008_bib28","doi-asserted-by":"crossref","first-page":"2482","DOI":"10.1056\/NEJMoa1205624","article-title":"Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis","volume":"367","author":"EVOLVE Trial Investigators","year":"2012","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.beem.2013.02.008_bib29","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1097\/TP.0b013e31826c3968","article-title":"Cinacalcet for the treatment of hyperparathyroidism in kidney transplant recipients: a systematic review and meta-analysis","volume":"94","author":"Cohen","year":"2012","journal-title":"Transplantation"},{"key":"10.1016\/j.beem.2013.02.008_bib30","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1007\/s00467-012-2186-9","article-title":"An open-label study to evaluate a single-dose of cinacalcet in pediatric dialysis subjects","volume":"27","author":"Padhi","year":"2012","journal-title":"Pediatric Nephrology"},{"key":"10.1016\/j.beem.2013.02.008_bib31","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1053\/j.ajkd.2008.09.021","article-title":"A randomized, double-blind, placebo-controlled study to assess the efficacy and safety of cinacalcet HCl in participants with CKD not receiving dialysis","author":"Chonchol","year":"2009","journal-title":"American Journal of Kidney Diseases"},{"key":"10.1016\/j.beem.2013.02.008_bib32","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1138\/20080318","article-title":"Anabolic therapy for osteoporosis: calcilytics","volume":"5","author":"Nemeth","year":"2008","journal-title":"IBMS BoneKEy"},{"key":"10.1016\/j.beem.2013.02.008_bib33","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1002\/jbmr.554","article-title":"Ronacaleret, a calcium-sensing receptor antagonist, increases trabecular but not cortical bone in postmenopausal women","volume":"27","author":"Fitzpatrick","year":"2012","journal-title":"Journal of Bone and Mineral Research"},{"key":"10.1016\/j.beem.2013.02.008_bib34","series-title":"A Phase IIb, randomized, placebo-controlled, dose-ranging study of MK-5442 in the treatment of postmenopausal women with osteoporosis","author":"Halse","year":"2012"},{"key":"10.1016\/j.beem.2013.02.008_bib35","doi-asserted-by":"crossref","first-page":"2935","DOI":"10.1002\/jbmr.520","article-title":"Osteoblast extracellular Ca2+-sensing receptor regulates bone development, mineralization, and turnover","volume":"26","author":"Dvorak-Ewell","year":"2011","journal-title":"Journal of Bone and Mineral Research"}],"container-title":["Best Practice & Research Clinical Endocrinology & Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521690X13000262?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521690X13000262?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T16:47:00Z","timestamp":1761497220000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521690X13000262"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,6]]},"references-count":35,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2013,6]]}},"alternative-id":["S1521690X13000262"],"URL":"https:\/\/doi.org\/10.1016\/j.beem.2013.02.008","relation":{},"ISSN":["1521-690X"],"issn-type":[{"value":"1521-690X","type":"print"}],"subject":[],"published":{"date-parts":[[2013,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Calcimimetic and calcilytic drugs for treating bone and mineral-related disorders","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Endocrinology & Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.beem.2013.02.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}